Sheffler LR, Taylor PN, Bailey SN, Gunzler DD, Buurke JH, IJzerman MJ, Chae J: Surface peroneal nerve stimulation in lower limb hemiparesis: effect on quantitative gait parameters. Am J Phys Med Rehabil 2015;94:341Y357. Objective: The objective of this study was to evaluate possible mechanisms for functional improvement and compare ambulation training with surface peroneal nerve stimulation vs. usual care via quantitative gait analysis.
Several recent studies have suggested that the daily use of a peroneal nerve stimulator (PNS) may facilitate motor recovery of the lower limb in patients with poststroke hemiparesis. 1Y3 However, in the authors' recently published randomized controlled trial of 12 wks of ambulation training with a surface PNS vs. usual care (UC) in chronic hemiparesis, there was no evidence of a therapeutic effect as measured by the Fugl-Meyer (FMA) score, the primary measure of lower limb motor impairment. 4 However, both PNS and UC treatment groups demonstrated significant improvement in functional mobility at the end of treatment, as measured by the tasks of the modified Emory Functional Ambulation Profile, which was maintained at 6-mo follow-up. The explanation for improvement on a measure of activity limitation in response to a treatment intervention, in the absence of improvement on the primary motor impairment measure, is unclear. It is possible that both the PNS and UC treatments conveyed focal therapeutic effects not detectable by the FMA score. Alternatively, compensatory strategies, not specific to the treatment intervention, may have been acquired during the treatment period resulting in sustained improvement in functional mobility. Examples of compensatory strategies include a change in proximal kinematics or kinetics of the paretic lower limb. Further, the improvement in functional mobility, in both PNS and UC groups, may have been induced by triggering either the same or different strategies for motor recovery and/or compensatory behaviors. If different strategies were used, then one of the two treatments may produce a more effective response to facilitate long-term motor recovery and may thus be preferable. The primary objective of this analysis was to evaluate possible mechanisms responsible for the improvement in functional mobility, which was evident in both the PNS and UC groups after 12 wks of ambulation training, by comparing the effect of treatment on spatiotemporal, kinematic, and kinetic parameters of gait.
METHODS

Study Design
A randomized controlled trial was performed, comparing ambulation training with a surface PNS to UC. Chronic hemiparetic stroke subjects were treated for 12 wks (device use period) and followed up for a total of 6-mo posttreatment. Outcome assessments (OA) were performed at baseline (t1), end of the device use period (t2), as well as at 12 wks (t3) and 24 wks (t4) after treatment. All outcome assessments, including quantitative gait analysis (QGA), were performed while the subject was not wearing the treatment device.
Subjects
Subjects were recruited from and treated at an academic medical center. Quantitative gait analyses were conducted in the Motion Studies Laboratory at a veterans affairs medical center. The institutional review boards of both institutions approved the study protocol, and all participants signed informed consent. Inclusion criteria were age of 18 yrs or older, 12-wk poststroke with unilateral hemiparesis or longer, and ankle dorsiflexion (DF) strength of 4/5 or less on the Medical Research Council scale. The subjects were required to ambulate 30 ft or longer without an ankle-foot orthosis (AFO) and a score of Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands (MJI); and Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio (JC).
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All correspondence and requests for reprints should be addressed to: Lynne R. Sheffler The authors certify that one author has an affiliation with or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants and patents received, or pending royalties) with an organization or entity with a financial interest in, or financial conflict with, the subject matter or materials discussed in the article; all such affiliations and involvements are disclosed as follows: Author PNT is the coinventor of the peroneal nerve stimulation device evaluated in this study and holds the patent for the device. There are no disclosures for authors LRS, SNB, DDG, JHB, MJI, and JC. 24 or higher on the Berg Balance Scale. Subjects were excluded for lower extremity edema, knee hyperextension during stance phase of gait, skin breakdown, or absent sensation; serious cardiac arrhythmias, pacemakers, or other implanted electronic systems; pregnancy; uncontrolled seizure disorder; concomitant lower motor neuron dysfunction and nonstroke upper motor neuron dysfunction; uncompensated hemineglect; sensory or motor peripheral neuropathy; fixed ankle plantarflexor contracture; or lower extremity botulinum toxin injection within the 3 mos before enrollment. All of the subjects were tested with the PNS device, before enrollment, to ensure that the subject could safely and effectively use the device if randomized to the PNS treatment group.
Randomization Procedure
Because poststroke motor outcomes may be affected by baseline motor function, 5,6 eligible subjects were first stratified on the basis of presence (Q1/5) or absence (0/5) of volitional ankle DF before being randomized to the PNS or UC group. The randomization sequence was concealed in consecutively numbered envelopes, which were allocated once eligibility was determined. Within the UC treatment group, the treatment device (AFO or no device) assigned to each subject was determined using standard-of-care clinical decision making based on observational gait pattern with subjects with milder DF weakness generally assigned to no device and subjects with more significant DF weakness being assigned an AFO.
Devices
The PNS device was the Odstock Dropped-Foot Stimulator 7Y9 (Odstock Medical Limited, United Kingdom), a single-channel surface stimulator that detects heel rise at preswing via a 3-mm insole pressure-sensing footswitch. The custom molded hinged AFO with plantarflexion block was fabricated using conventional techniques (G.A. Guilford & Son Ltd, Brookpark, OH).
Intervention
The 12-wk device use (treatment) period consisted of a functional training phase (two 1-hr therapy sessions per week Â 5 wks) and a postfunctional training phase (three additional 1-hr therapy sessions over the remaining 7 wks). During the functional training phase, the subjects were trained to use their treatment devices for home and community mobility with an assistive device (AD), such as a straight cane, quad cane, or walker, if needed. The content of the device use therapy sessions was standardized across the treatment groups with the only between-group difference being the treatment device used in the therapy session. Therapy content included passive and active range of motion exercises, lower extremity strengthening (supine and standing), standing balance activities, weight-shifting activities to the affected limb using parallel bars with transition to least restrictive gait AD, and refinement of a reciprocal gait pattern (visual and manual cues were given). Exercises were done with multiple repetitions with increase in difficulty and decrease in cues, with and without the assigned treatment device, as appropriate. A focus of the therapy sessions was on higher level gait activities including functionally relevant movement tasks such as stair climbing, walking on various surfaces (tile, carpet, ramps), negotiation of obstacles, community stepping (curbs), and treadmill training, as appropriate Both treatment groups received the same total amount of therapy hours during the 12-wk device use period.
The subjects independently used their treatment devices up to 8 hrs per day during the device use period once device safety was demonstrated. At each therapy session, treatment device function, application, and use guidelines were reviewed with the subject to maximize device compliance. At completion of the device use period, all subjects discontinued use of the assigned treatment device.
Outcome Assessments
Quantitative Gait Analysis
Quantitative gait analysis was performed using a Vicon system (Vicon Motion Systems Limited, Oxford, United Kingdom), a motion measurement and analysis system that tracked the trajectories of reflective markers in the field of view of multiple cameras mounted around the periphery of the laboratory. Retroreflective markers were adhered to the skin at anatomic locations following a modified Helen Hayes marker set. 10, 11 The subjects were asked to ambulate 10 m at a self-selected comfortable rate while not wearing the treatment device. A minimum of 20 strides (approximately 10 trials) was collected at each outcome assessment. Infrared strobe lights mounted on each camera illuminated the measurement space. AMTI Biomechanics Platforms (Advanced Mechanical Technology, Inc, Watertown, MA) were embedded in the walkway of the laboratory. Joint motion was measured approximately 3 axes using standard Vicon plug-in-gait nomenclature. Illumination, motion capture data, and analog-to-digital conversion of transducer input were synchronized and controlled by the Vicon system, which was, in turn, controlled by a Pentiumbased PC. Data were processed using the Vicon Plug-In-Gait biomechanical model in Vicon supplied to generate joint angles, moments, powers, and spatiotemporal parameters of gait. Midway through the study (after enrollment of 48 subjects), the gait laboratory Vicon system underwent a hardware update from Vicon 370 to Vicon MX, which resulted in the camera sampling frequency increasing from 60 to 100 Hz, and a software change from Workstation to Nexus. After the Vicon system upgrade, all methods of data collection and analysis were kept consistent by following the standard Vicon Plug-In Gait model methods. At each QGA assessment, the subjects used the AD (no device, straight cane, quad cane, or walker) determined to be most clinically appropriate for gait safety and stability. However, all QGAs were preferentially performed without an AD and withinsubject AD consistency was maintained across testing sessions if appropriate. All QGA sessions were performed under the direction of the same gait laboratory engineer.
For purposes of the primary analyses, specific spatiotemporal, kinematic, and kinetic parameters of gait were identified a priori on the basis of clinical relevance to treatment intervention. The authors of this study report the following spatiotemporal parameters: cadence (in steps per minute), double support time (in seconds), stride length (in meters), and walking speed (in meters per second). The authors of this study report the following proximal kinematic parameters: peak hip flexion angle in swing (in degrees) and peak knee flexion angle in swing (degrees) of the paretic lower limb. For purposes of a secondary analysis (see below), peak hip extension of the paretic limb during stance was additionally recorded. The three-dimensional movement of the ankle joint, which characterized foot position, was recorded as the degree of movement away from the neutral position in the sagittal (DF/plantarflexion), coronal (ankle abduction/adduction), and transverse (ankle external/ internal rotation) planes. The authors of this study report the following distal kinematic parameters of the paretic ankle: DF angle at initial contact (in degrees), peak ankle DF angle in swing (in degrees), peak ankle abduction angle in swing (in degrees), and peak ankle external rotation angle in swing (in degrees). Lastly, the authors of this study report the following kinetic parameters of gait: peak anteriorposterior (AP) ground reaction force (GRF) (in newton per kilogram), peak hip power in preswing (in watts per kilogram), and peak ankle power at push-off (in watts per kilogram) of the paretic lower limb.
Activity Monitor
The ActivPAL monitor (PAL Technologies Ltd, Glasgow, United Kingdom) was used to record subject activity over a 3-day consecutive period at each outcome assessment. The ActivPAL is an accelerometerbased activity logger that records the time spent standing, time spent stepping, and total number of steps taken over a given period. Each subject was issued an ActivPAL device at the time of each outcome assessment and given standardized instruction on application and 3-day use of the monitoring device. In this study, average daily time spent standing (in minutes), average daily time spent stepping (in minutes), and average total steps per day were evaluated and used as a proxy for overall activity level at each time point.
Statistical Analysis
The original randomized controlled trial was designed as a 2 Â 2 factorial design with treatment group (PNS vs. UC) and DF status (present vs. absent) as between-subject factors. The study was powered using the FMA score, which was the primary motor impairment outcome measure. However, during subject accrual, the authors of this study experienced uneven recruitment, with only 26% of the subjects assigned to the DF absent group. Thus, the study was converted to a single-factor design (PNS vs. UC) with anticipated difference in FMA score (primary motor impairment outcome7 measure) between groups of 5 points (SD, 0.83), which increased the power of the study to 99%. The stratification on DF status was maintained during randomization to ensure even distribution of baseline motor function. All analyses were performed as intent-to-treat. Pretreatment gait parameters were evaluated for mean and standard deviation. Each outcome was modeled using a linear mixed-effects approach to evaluate the mean change in the outcome measures with treatment group. Time was considered discrete because measurements were made at the four time periods (0, 12, 24, and 36 wks). However, because there was some variation in the exact date that individual measurements took place, the authors of this study allowed for different growth rates for individuals by including a random intercept and slope in the models. Mixed-effects models are well suited for handling correlated repeated measurements, missing data, and dropouts in longitudinal studies. 12 In this study, the models yielded estimates of the treatment group main effect, treatment group Â time effect, and time effects while permitting the authors to control for potential confounders. The authors of this study adjusted for potential confounders including age, sex, interval poststroke, involved hemisphere, and stroke type (ischemic vs. hemorrhagic). Plots of least-square (LS) means over time were generated for each of the gait variables providing correction for missing data and estimating the marginal means for a balanced population while adjusting for the confounders in the model.
To assess the effect of the treatment intervention on spatiotemporal, kinematic, and kinetic parameters over time, of primary interest was the two-way interaction between treatment group and time. The authors of this study used an unstructured covariance structure, which made no assumptions about the variances and covariances, and allowed for differences in variability of the measurements at each time point. Model estimation was performed via restricted maximum likelihood using PROC MIXED in SAS Version 9.2. 13 The authors of this study used a Bonferroni correction to control the family-wise error rate and report the authors' adjusted P values. The authors of this study also modeled all outcomes using a more robust estimator for the standard error (EMPIRICAL option in PROC MIXED), which would confirm that parametric assumptions of the model were not violated. 14 Three secondary analyses were performed using the same statistical methods as reported previously, after review of the primary analyses suggested additional research hypotheses (see Discussion). These analyses included (1) the effect of treatment device on hip range of motion (approximated by the difference between peak hip flexion during swing and peak hip extension in stance measured via QGA); (2) an exploratory analysis of the differential effect of treatment device on peak DF angle in swing within the UC group (AFO, 48 subjects; ND, 8 subjects); and (3) an analysis of spatiotemporal, kinematic, and kinetic data, limited to the subset of subjects who used no AD (straight cane, quad canes, or walker) at any of their OAs, to eliminate the potential confound of an AD, particularly on the kinetic data.
RESULTS
Participants and Baseline Characteristics
A total of 110 stroke survivors were enrolled in the study. Fifty-four were randomized to the PNS group; 56, to the UC group. Forty-eight subjects (86%) randomized to UC were treated with an AFO; eight subjects (14%) were treated with no device. Subject dropout rates at t1, t2, t3, and t4 were 2%, 13%, 15%, and 24%, respectively. 4 As previously reported, there were no significant differences in baseline characteristics (age, sex, interval poststroke, stroke type, hemisphere, lower extremity FMA score, 
Primary Analyses Spatiotemporal Parameters
The treatment group main effect, which reflects pretreatment between-group differences, was significant for cadence (F 1,187 = 20.06, P G 0.001) (cadence being greater in the UC group) but not double support time, stride length, or walking speed. The treatment group Â time interaction effect was not significant for any of the four spatiotemporal parameters. The time effect for double support time was also not significant. However, the time effect was significant for cadence (F 3,153 = 5.81, P = 0.012), 
Kinematic Parameters
The treatment group main effect was not significant for any of the kinematic parameters. Treatment group Â time interaction effect and time effect were not significant for peak hip flexion angle during swing, peak knee flexion angle during swing, ankle DF angle at initial contact, peak ankle abduction angle during swing, or peak ankle external rotation during swing. Treatment group Â time interaction effect for peak ankle DF angle during swing was also not significant; however, there was a significant time effect (F 3,184 = 4.99, P = 0.031) with the subjects in both groups experiencing a reduction in peak ankle DF angle during swing. The post hoc analysis showed significant decreases in peak DF angle during swing at t2 and t3, both relative to t1. Figure 4 shows the plot of LS means over time for peak ankle DF angle in swing.
Kinetic Parameters
The treatment group main effect was significant for peak hip power in preswing (P = 0.003) (pretreatment peak hip power was greater in the UC group) but not AP GRF or peak ankle power at pushoff. There was no significant treatment group Â time interaction effect for peak AP GRF, peak hip power in preswing, or peak ankle power at push-off. The time effect was significant for peak AP GRF (F 3,164 = 6.61, P = 0.004) with the post hoc analysis showing significant improvement at both t2 and t4 relative to t1. The time effect was significant for peak hip power in preswing (F 3,156 = 8.76, P G 0.001) and the post hoc analysis showed significant improvement at t2, t3, and t4 relative to t1. Lastly, the Walking speed improved over time in both treatment groups, although the betweengroup difference was not significant.
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Nerve Stimulation in Lower Limb Hemiparesis time effect was significant for peak ankle power at push-off (F 3,149 = 6.38, P = 0.005), and the post hoc analysis showed significant improvement at t2, t3, and t4 relative to t1. Figures 5 and 6 are plots of LS means over time for peak hip power in preswing and peak ankle power at push-off, respectively. Table 3 presents the mean T standard deviation of the three activity parameters measured by the ActivPAL monitor by treatment group at t1, t2, and t3, and t4. For all parameters, the treatment group main effect was not significant. The time effects for average time standing (F 3,151 = 1.05), average time walking (F 3,148 = 0.54), and average number of steps per day (F 3,153 = 0.78) were not significant (P 9 0.999). Similarly, the treatment group Â time effects for average time standing (F 3,151 = 0.57), average time walking (F 3,148 = 1.13), and average number of steps (F 3,153 = 0.78) were not significant (P 9 0.999).
Activity Level
Assistive Devices
AD designations were the following: no device, straight cane, quad cane, or walker. Table 4 details AD use across the QGA assessments. Of the 54 subjects in the PNS treatment group, 41 subjects used the same AD for all of the QGA assessments. Within this group of 41 subjects, 27 used no device for all of the QGA assessments. Of the 56 subjects in the UC treatment group, 44 subjects used the same AD for all of the QGA assessments. Within this group of 44 subjects, 25 used no device for all QGA assessments. Table 5 presents interval change in AD use for subjects who used a different device at any of their QGA assessments. 
Secondary Analyses
An analysis of hip range of motion (approximated by the difference between peak hip flexion during swing and peak hip extension measured via QGA) demonstrated a significant time effect (F 3,198 = 9.4, P G 0.0001) with both treatment groups gaining approximately 3 degrees of active range of motion by t4, although a treatment group Â time interaction effect was not found (F 3,205 = 2.12, P = 0.099).
An exploratory analysis limited to the UC group (AFO, 48 subjects; ND, 8 subjects) showed a significant treatment group (AFO vs. no device) by time interaction effect (F 3,87 = 3.32, P = 0.023) favoring the no device group; the post hoc analysis found the difference to be significant at t2 and t3 relative to t1. Figure 7 shows the plot of LS means over time of peak DF angle in swing within the UC treatment group.
An analysis of the subset of subjects who used no AD for all of their QGA assessments (PNS, n = 27; UC, n = 25) ( Table 6 ) showed no significant group effect or treatment group Â time interaction for any of the spatiotemporal, kinematic, and kinetic parameters. Time effect was significant for cadence (F 3,73 = 5.34, P = 0.029), stride length (F 3,78 = 12.72, P G 0.001), and walking speed (F 3,74 = 12.01, P G 0.001). The post hoc analysis showed significant differences at t2, t3, and t4 relative to t1 for both cadence and walking speed as well as a significant difference at t4 relative to t1 for stride length. Time effect was not significant for the kinematic parameters. Time effect was significant for AP GRF (F 3,101 = 7.05, P = 0.003) and peak hip power in preswing (F 3,81 = 13.29, P G 0.001). The post hoc analysis showed significant improvements at t2, t3, and t4 relative to t1 for peak hip power in preswing and at t4 relative to t1 for AP GRF.
DISCUSSION
A primary finding of this study was that both PNS and UC groups experienced significant improvements in peak hip power in preswing and peak ankle power at push-off of the paretic lower extremity during the treatment phase, which was maintained at the 6-mo posttreatment. Given that the change was most apparent at t2, a reasonable explanation is that the therapy session activities, which were common to both groups and performed during the device use period, increased hip and ankle muscle strength, muscle mass, and/or motor control, resulting in improved hip and ankle power. Alternatively, study participation and/or prescription of either DF-assisted device may have inspired a general increase in walking, exercise, or overall activity level during the device use period and beyond, which resulted in improved hip and ankle power in both groups. This second explanation is less likely because the ActivPAL data, which were recorded at each outcome assessment and used as a proxy for overall level of activity, show Within-subject AD use was consistent for 41 subjects in the PNS group (77%) and 44 subjects in the UC group (80%).
TABLE 5 Change in the AD by treatment interval
for those subjects who used a different device at any of their QGA assessments (PNS = 12, UC = 11)
Interval t0Yt1
Interval t1Yt2
Interval t2Yt3
Change: QC to cane 7: Of note, improvements were noted in both treatment groups despite a treatment group main effect that favored the UC group for peak preswing hip power at baseline. Although a significant treatment group main effect was unanticipated given the subject stratification, this finding suggests that a higher level of motor impairment may not preclude a positive response to an ambulation training intervention in chronic stroke. An interesting observation is that paretic ankle power at push-off improved at the end of the device use period in the UC group despite relative ankle movement restriction imposed by an AFO in most of the UC subjects. Although the small numbers of subjects preclude definitive statistical conclusions, this observation poses additional research hypotheses about a theoretical clinical concern that restriction of ankle movement within an AFO may be detrimental to residual paretic ankle strength and/or increase the metabolic cost of walking. 15 In this study, each AFO had a hinge that allowed limited DF range for those subjects in whom it was clinically appropriate. If, in fact, ankle strength improved in the subset of UC subjects who used an AFO, it is possible that eccentric contraction during midstance (before heel-off) and concentric contraction at beginning push-off of the gastrocsoleus muscles, within the allowable AFO ankle range and in the setting of a 12-wk period of gait training, were sufficient to mitigate deleterious effects on ankle strength or power that might have been observed with a solid ankle AFO. Alternatively, ankle power during the device use period may have improved in the UC group if AFO compliance was poor, which, in the absence of reliable data on use, cannot be known.
Subjects in both treatment groups experienced significant improvements in cadence, stride length, and walking speed during the device use period, which was maintained at the 6-mo posttreatment. However, despite subject stratification based on motor impairment, a treatment group main effect was noted for cadence favoring the UC group at baseline. To test the hypothesis that an improvement in hip range of motion may have contributed to increased cadence and stride length, a secondary analysis of hip range of motion (approximated by the difference between peak hip flexion during swing and peak hip extension measured via QGA) was performed, which demonstrated a significant time effect with both treatment groups gaining approximately 3 degrees by t4, although a treatment group Â time interaction effect was not found. Lastly, improvements in walking speed may be primarily related to the improvement noted in preswing hip and ankle push-off power. Jonkers et al. 16 found that, similar to able-bodied control subjects, higher-functioning stroke survivors increased their walking speeds by increasing both paretic hip and ankle power generation. Similarly, Mulroy et al. 17 found that improved walking speeds during poststroke treadmill training with body-weight support were associated with increased paretic hip flexion power.
Multiple studies, which have evaluated a variety of poststroke gait interventions, including task-oriented biofeedback, 18 virtual reality training, 19 task-oriented physical therapy with and without rehabilitation technology, 20 robotic gait training, 21 and treadmill gait retraining augmented via visual electromyographic biofeedback, 22 have also concluded that interventionassociated functional gains were largely attributable to an increase in paretic ankle power. On the basis of these data, the best explanations for the improvement in functional mobility reported in the authors' earlier study 4 are improvements in peak hip power in preswing and peak ankle power at push-off. An unanticipated finding, which merits further investigation in a future, appropriately powered study, was that both PNS and UC groups experienced worsening of peak DF angle during swing during the treatment period, which persisted at the 3-mo posttreatment but not at the 6-mo posttreatment. This finding suggests that wearing either device may have a detrimental effect on peak DF in swing. If this hypothesis were true, one possible explanation might be that the daily use of either device reduces the need for volitional drive to dorsiflex the ankle during swing, albeit through different mechanisms. The effect of functional electrical stimulation on motor cortical excitability depends on the concurrent motor cortical drive present at the time of stimulation, and the combination of these factors is proposed to modulate neural excitability. 23 It can be hypothesized that repetitive surface peroneal nerve stimulation used during walking decreases the concurrent motor cortical drive, which might otherwise be present and necessary to achieve maximal DF during the swing phase of gait.
Speculating further, an AFO may reduce peak DF via several mechanisms. Similar to PNS, the magnitude of concurrent motor cortical drive may be less when wearing an AFO owing to the AFO functioning to keep the ankle at a neutral angle throughout the gait cycle. It is also possible that inhibition of active contraction of the anterior tibialis by the rigidity of an AFO results in loss of DF muscle mass and/or strength. To further explore the hypothesis that the continual use of an AFO reduces peak DF angle, an additional exploratory analysis of the UC group (AFO, 48 subjects; ND, 8 subjects) was performed using the previously noted robust statistical methods. The analysis showed a significant treatment group (AFO vs. no device) by time interaction effect that was significant at both t2 and t3 and approached significance at t4. Consistent with the authors' hypothesis, Figure 5 shows that peak DF angle in swing decreased for the AFO subset during the device use period, but it modestly increased for the no-device subset. This additional analysis should be interpreted as exploratory and hypothesis-generating only because of statistical limitations associated with the small and unequal sample sizes within the UC treatment group.
Regardless of mechanism, these results suggest that extended DF-assisted device use (PNS or AFO) may be detrimental, although the clinical significance of an approximate 3-degree loss of peak ankle DF during swing is unclear as other clinically relevant gait parameters improved in both groups (stride length, cadence, walking velocity). The absence of treatment by time effect on DF angle at initial contact, ankle external rotation, or ankle abduction during swing additionally suggests that neither treatment group benefitted from a therapeutic effect or compensatory strategy that specifically improved ankle positioning either at heel strike or throughout the gait cycle.
An important potential confound in this trial was the unknown effect of any AD (straight cane, quad cane, or walker) used during the QGA session, particularly on the kinetic data recorded. Although all QGAs were preferentially performed without an AD and within-subject AD consistency maintained across testing sessions as possible, the use of an AD to provide gait stability and safety during the QGA session was ultimately a clinical decision, made by the research staff present at each outcome assessment. Within-subject AD consistency was 77% and 80% in the PNS and UC treatment groups, respectively (Table 3 ). Of those subjects who used a different AD at any given QGA session (PNS, n = 12; UC, n = 11), most subjects in both treatment groups showed improvement with subsequent sessions, as demonstrated by transitioning from a greater to lesser device (i.e., quad cane to straight cane or straight cane to no device) ( Table 4) . A secondary analysis, which was limited to subjects who did not use an AD for any of their QGA assessments (n = 52), showed results similar to those of the primary analysis (n = 110) ( Table 5 ). There was no evidence of a treatment effect favoring one DF-assisted device over the other, although improvements were noted in cadence, stride length, and walking speed in both treatment groups, most pronounced at t2, also associated with an increase in peak hip power in preswing. In contrast to the larger analysis, the time effect was not significant for peak ankle power at push-off in this subset of subjects. This finding is consistent with a recent study by Polese et al., 24 which demonstrated an increase in ankle power generation with the use of a cane (Bwalking stick[) in poststroke survivors. The lack of a time effect suggests that the increase in peak ankle power at push-off in both treatment groups in the larger analysis may be, in part, related to use of an AD. Definitive analysis of the contribution of an AD on the kinetics of gait in this study would have required that QGA be performed under multiple AD conditions at each outcome assessment.
In summary, this study failed to demonstrate the superiority of PNS over UC in reducing lower extremity motor impairment and activity limitation in chronic stroke survivors. However, subjects in both treatment groups exhibited improvements in paretic ankle push-off power and, specifically, preswing hip power, which likely contributed to the improvements in the spatiotemporal parameters in the present report and improvement in functional mobility (modified Emory Functional Ambulation Profile scores) described in the authors' earlier publication. 4 It seems that gait training with either PNS or UC conveyed focal therapeutic effects, detectable by QGA, which were not detectable by the FMA, a global measure of motor impairment. This study also adds to the growing body of evidence 25,26 that rehabilitation interventions in the chronic phase of stroke can be clinically relevant and further contributes to the debate 27 regarding specificity of poststroke gait treatment. Study limitations are primarily related to study design and include (1) the inability to determine the role of baseline DF function due to a single factor design, (2) the lack of clear knowledge of the minimal clinically significant difference for each of the gait parameters, (3) lack of accurate treatment device use data, (4) unknown optimal treatment device duration, (5) potential confound of DF-assisted device used, if any, between t2 and t4 assessments, (6) potential confound of offset between different assessments (marker placement) that may influence kinematic data, and (7) relatively large dropout rate of 24% by 6 mos, which may have compromised internal validity. Lastly, a final important consideration is that compensatory strategies may have been acquired during the treatment period related to biomechanics of the nonparetic limb. An analysis of the kinematic and kinetic data from the nonparetic limb, although outside the scope of this present analysis, may provide further understand-ing of compensatory mechanisms in poststroke gait recovery.
CONCLUSIONS
Both PNS and UC treatment groups demonstrated increased paretic preswing hip power and ankle power at push-off (measures of motor impairment) that translated into significant improvement in stride length, cadence, and walking velocity (measures of functional ambulation), which were sustained at the 6-mo posttreatment. Thus, the QGA was able to demonstrate a therapeutic effect in both groups that was not previously evident using only the FMA. These results suggest that the same mechanism for motor recovery is responsible for the improvement in functional ambulation that was evident in both groups of chronic hemiparetic stroke survivors at the end of the device use period. However, there was no evidence of a treatment effect on any of the spatiotemporal, kinematic, or kinetic gait parameters that would make either the PNS or UC treatments preferable to the other. The decrease in peak ankle DF during swing in both the PNS group and the AFO subjects within the UC group merits further investigation. 
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